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Renal sympathetic denervation (RDN) has been and is still proposed as a new treatment
modality in patients with apparently treatment resistant hypertension (TRH), a condition
defined as persistent blood pressure elevation despite prescription of at least 3
antihypertensive drugs including a diuretic. However, the large fall in blood pressure after
RDN reported in the first randomized study, Symplicity HTN-2 and multiple observational
studies has not been confirmed in five subsequent prospective randomized studies and
may be largely explained by non-specific effects such as improvement of drug adherence
in initially poorly adherent patients (the Hawthorne effect), placebo effect and regression
to the mean. The overall blood-pressure lowering effect of RDN seems rather limited
and the characteristics of true responders are largely unknown. Accordingly, RDN is not
ready for clinical practice. In most patients with apparently TRH, drug monitoring and
improvement of drug adherence may prove more effective and cost-beneficial to achieve
blood pressure control. In the meantime, research should aim at identifying characteristics
of those patients with truly TRH who may respond to RDN.
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INTRODUCTION
Renal sympathetic denervation (RDN) has been and is still pro-
posed as a new treatment modality in patients with apparently
treatment resistant hypertension (TRH), a condition defined as
persistent blood pressure elevation despite prescription of at
least 3 antihypertensive drugs including a diuretic (Krum et al.,
2009, 2014; Esler et al., 2010). However, with the recent publi-
cation of the Symplicity HTN-3 study in the U.S. (Bhatt et al.,
2014) it is questioned whether RDN at all lowers blood pres-
sure (Demaria, 2014). During 2014, a total of 5 prospective and
randomized studies of RDN showing modest or no effect on
blood pressure in patients with TRH have been published or
presented. Other recent studies have shown that patients with
TRH have surprisingly low drug adherence. The aim of this paper
is to review all prospective and randomized studies of RDN
in TRH and, and to review the issue of poor drug adherence
and suggest therapeutic drug monitoring (TDM) as a cost-
effective modality to control blood pressure and improve prog-
nosis in this subset of hypertensive patients who are at risk and
difficult-to-treat.
Abbreviations: ABPM, ambulatory blood pressure monitoring; RDN, renal sym-
pathetic denervation; TRH, treatment resistant hypertension; TDM, therapeutic
drug monitoring.
THE RISE AND FALL OF RENAL DENERVATION IN
TREATMENT RESISTANT HYPERTENSION
The initial enthusiasm followed by the setback of RDN can prob-
ably be summarized by a handful of explanations: (1) The role of
the sympathetic system in the pathophysiology of hypertension
is substantiated by a wealth of experimental and clinical argu-
ments (Julius and Esler, 1975; Eide et al., 1979; Kjeldsen et al.,
1981). On this background, enthusiasm surged when an inter-
vention in this system seemed to drastically lower blood pressure.
(2) Market-driven industry interests significantly influenced the
medical community. (3) Subsequently, pitfalls in the treatment
of apparent TRH patients, which are simple but well-known for
decades, were suddenly forgotten, including well described phe-
nomena such as the placebo effect, poor drug adherence (Gifford,
1988; Klein, 1988; Ceral et al., 2011) and the Hawthorne effect
(Mangione-Smith et al., 2002). Regression to the mean could
also be involved which means that abnormal BP values tend to
change toward normalization without an underlying biological
explanation.
The first and for a long time the only prospective random-
ized clinical trial in this field, the Symplicity HTN-2 study (Esler
et al., 2010), was monitored by Ardian (Medtronic) who col-
lected and processed the data. Usually, when such a task is given
to industry, all measures are taken to secure confidence and
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trials are double-blinded (Julius et al., 2004). However, in this
case, everything was open, making the trial particularly vul-
nerable to patient and physician related biases (Howard et al.,
2013). In a recent editorial (Shun-Shin et al., 2014), the authors
wrote that “measurement of a noisy variable by unblinded opti-
mistic staff is a known recipe for calamitous exaggeration.” It is
also unfortunate that selection of patients enrolled in Symplicity
HTN-2 and evaluation of efficacy were based on office rather
than ambulatory blood pressure measurements (ABPM), which
is state-of-the art (O’Brien et al., 2013), particularly in resistant
hypertension (Persu et al., 2014d). ABPM reduces observer bias
and measurement error, minimizes the white-coat effect and has
greater reproducibility, and therefore provides a better estimate
of a patient’s usual blood pressure and cardiovascular progno-
sis (Kikuya et al., 2007; Salles et al., 2008). Notwithstanding
the well-known, major contribution of poor drug adherence to
apparently resistant hypertension (Gifford, 1988; Klein, 1988;
Ceral et al., 2011), drug adherence was not monitored, either at
baseline or during follow-up. This made the study vulnerable to
the Hawthorne effect, i.e., patients changing behavior—in this
case starting taking their drugs as prescribed -, in response to the
intervention and massive attention devoted to them. The lack of
blood pressure decrease in the control group also raises concerns.
One would indeed suspect that patients in the control group had
not taken their medications properly, in order to keep their blood
pressure at a higher level that made them eligible for cross-over to
RDN group (Azizi et al., 2012; Persu et al., 2012). Finally, placebo
effect and regression to the meanmust also be taken into account.
Noteworthy, the placebo effect is small by using ABPM (Staessen
et al., 1996; O’Brien et al., 2013); however, ABPM remains as
sensitive to the Hawthorne effect as office blood pressure.
THE ROLE OF INDUSTRY IN PROMOTING RENAL
DENERVATION
Despite the major limitations and potential biases of Symplicity
HTN-2, RDN was adopted in hundreds of centers worldwide.
Medtronic Inc® (Minneapolis, Minnesota) paid $800 million to
purchase Ardian® (Mountain View, California), the company
that had developed the technology (Demaria, 2014), and more
than 10 companies developed their own RDN systems, five of
which obtained the CEmark (Conformité Européenne, European
Conformity). CE marking means that the product is assessed
before being placed on the market and meets EU safety, health
and environmental protection requirements. However, CE mark-
ing is unrelated to medical indication at variance with the USA
where FDA approves a medical device only when it has been
tested and proved effective for a certain medical condition. The
procedure was quickly reimbursed in Germany, and later on in
Switzerland, Sweden and the Netherlands. While RDN remained
an investigational procedure in the U.S., at least 8000 (Lüscher
and Mahfoud, 2014), possibly 15,000–20,000 procedures were
performed in Europe and in the rest of the world in less than
4 years, most of them using the Ardian -Medtronic® catheter.
It may be hypothesized that the massive incomes, generated by
selling the Symplicity catheter to enthusiastic Europeans paid for
the Symplicity HTN-3 study (Bhatt et al., 2014), required by the
FDA before approval of RDN in the U.S. In Symplicity HTN-3,
blinding of patients through the use of a sham procedure and
wider use of ABPM balanced and limited the differential impact
of the Hawthorne, white coat, placebo and regression to the mean
effects in both arms, disclosing to the world the true size of blood
pressure decrease attributable to RDN, at least in patients meeting
the Symplicity criteria; it was less than 2mmHg systolic based on
ABPM.
For all aforementioned reasons, and in view of the complexity
and multifactorial character of hypertension, the failure of RDN
to normalize or substantially reduce blood pressure in all patients
with apparently TRH was a reasonable working hypothesis for
us, even before the Medtronic announcement that Symplicity
HTN-3 had failed to meet its primary endpoint (http://www.
tctmd.com/show.aspx?id=123265). We (Fadl Elmula et al., 2013;
Persu et al., 2013a,b) and others (Azizi et al., 2012; Howard et al.,
2013) had predicted that the true effect of RDN might have been
overestimated and may considerably shrink in properly designed
studies (Howard et al., 2013), and that “one size may not fit all”
(Persu et al., 2012). In particular, in preliminary analysis of the
European Network COordinating research on Renal Denervation
(ENCOReD) network (Persu et al., 2014a) we were struck by
the imbalance between the 17.6mmHg decreases in office blood
pressure, vs. only 5.9mmHg for 24-h ambulatory blood pressure.
FINDING PATIENTS WITH TRUE TREATMENT-RESISTANT
HYPERTENSION FOR RESEARCH
When we set out to investigate the effects of RDN in one of the
centers with the longest experience in conducting randomized
clinical trials in Europe (Helgeland, 1980), we had thus clearly in
mind the limitations of previous studies. We needed a simple and
practical way to deal with pitfalls in the recruitment of patients
with resistant hypertension into a study protocol: Patients had to
qualify for the RDN protocols by having elevated daytime ABPM
after witnessed intake of their prescribed blood pressure medica-
tion (Fadl Elmula et al., 2013). Meanwhile, a leading hypertension
center in Germany (Brinkmann et al., 2012) published a well-
documented series of patients whose blood pressure remained
unchanged after RDN. We were thus not surprised when we
found no change in either office or ABPM following RDN, first
in an open series of six patients (Fadl Elmula et al., 2013),
later followed by a randomized study (Fadl Elmula et al., 2014).
Patients who were randomly assigned to further improvement of
drug treatment guided by non-invasive hemodynamic monitor-
ing had normalized blood pressures (Figures 1, 2). In contrast,
patients exposed to RDN experienced only a small and proba-
bly partly placebo-induced fall in office and ABPM. The decreases
averaged 20mmHg more for office and 9mmHg more for ambu-
latory systolic blood pressure in the hemodynamically guided
drug treatment group (n = 10) compared to the RDN group
(n = 9). Because of sustained elevation of AMBP in the RDN
treated patients at 6 months of follow-up, we stopped randomiza-
tion for ethical reason according to a pre-specified decision (Fadl
Elmula et al., 2013).
THE PITFALLS WITH RENAL DENERVATION IN TREATMENT
RESISTANT HYPERTENSION
In the absence of solid evidence of efficacy, how can we explain
the uncontrolled deployment of RDN in Europe and worldwide
(with the notable exception of the U.S. where RDN remained
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FIGURE 1 | Shows the effect of RDN on office systolic blood pressure
(SBP) at 3-month and 6-months of follow-up, compared to drug
treatment adjustment guided by non-invasive hemodynamic
measurements. Differences were statistically significant (Fadl Elmula
et al., 2014), favoring drug treatment adjustment, which is the
recommended method to gain blood pressure control in patients with
so-called treatment-resistant hypertension (Gifford, 1988).
FIGURE 2 | Shows the effect of RDN on ambulatory daytime systolic
blood pressure (SBP) at 3-month and 6-months of follow-up,
compared to drug treatment adjustment guided by non-invasive
hemodynamic measurements. Differences were statistically significant
(Fadl Elmula et al., 2014), favoring drug treatment adjustment, which is the
recommended method to gain blood pressure control in patients with
so-called treatment resistant hypertension (Gifford, 1988).
an investigational procedure)? Of course, publications of the
Symplicity studies and multiple observational studies, and enthu-
siastic editorials and reviews in top-ranking journals (Mahfoud
et al., 2013; Ott et al., 2013) had a substantial impact, and the
lack of strict rules for introduction of device-based therapies in
Europe facilitated the large-scale implementation of the tech-
nique. However, this phenomenon would have remained limited
without the huge promotion by device-producing industry.
Probably industry has never launched such a strong campaign
to market a new technology before. A multitude of national
and international advisory boards organized educational meet-
ings, developed a website (www.poweroverpressure.com) and
produced guidelines, and corresponding author of this current
review contributed to these. Medical journals were swamped
by reviews and meta-analyses showing the powerful blood
pressure lowering effects as recorded in observational studies
and in the single available randomized study, Symplicity HTN-2.
Comments pointing out the defects and inconsistencies in such
meta-analysis encountered great delay in getting published (Jin
et al., 2014). Many never questioned whether RDN should be
implemented, but when it should start in an institution. By
all means, the purpose was to disseminate the enthusiasm for
RDN from the technically-oriented invasive radiologists and
cardiologists who usually had little interest or experience in the
treatment of hypertension to the “hypertension establishment.”
The European Society of Hypertension issued specific guidelines
(Schmieder et al., 2012, 2013), but maintained reservations
that more data was needed, and eventually it had to be proven
that RDN would lower morbidity and mortality before being
generally accepted in the treatment of true or apparent TRH.
In the aftermath of Symplicity HTN-3, it has been suggested
that the lack of demonstrated efficacy of RDN in Symplicity
HTN-3 may be due to lack of statistical power or even to chance
(Lüscher and Mahfoud, 2014) or that the trial was well con-
ceived but not rigorously executed (Esler, 2014; Schmieder, 2014;
White et al., 2014; Lobo et al., 2015). In particular, a fraction
of African American participants increased their antihyperten-
sive medication, contrary to protocol, which masked a potential
BP lowering effect of RDN in contrast to other participants.
In addition, legitimate concerns were raised as to whether the
denervation procedure was sub-optimal in many cases due to
insufficient delivery of appropriate energy in the renal arteries as
a consequence of the inexperience of the investigators. However,
this criticism is all post-hoc, and the Symplicity HTN-3 findings
are after all in line with the other RCTs published and presented in
2014 (Azizi et al., 2014; Desch et al., 2014; Fadl Elmula et al., 2014;
Rosa et al., 2015). Furthermore, the Symplicity HTN-3 results
are diluted by non-scientific comparisons with the Medtronic®
registry (Pathak et al., 2014) which is hampered by all the weak-
nesses touched upon in this review, and even more as it is a
pure industry-ran activity. Finally, while RDN will not become
available in the U.S., and ongoing research in Asia was stopped,
industry continues to make their catheters available for clinical
use and promotes the technique in Europe.
COULD THERE BE RESPONDERS TO RENAL DENERVATION
IN HYPERTENSION?
Does the failure of Symplicity HTN-3 mean the end of RDN?
Not necessarily. Indeed, it has been shown in cohorts recruited
from the third (The effect of progressive sympathectomy on
blood pressure, Bradford Cannon, 1931) until the fifth decade
of the last century (Smithwick and Thompson, 1953; Longland
and Gibb, 1954) that abdominal sympathectomy associated to
splanchnicectomy is effective in the treatment of severe hyperten-
sion. Accordingly, research should go on to find the minority of
patients who are true responders to RDN, and identify predictors
of effective RDN. The European Network COordinating research
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on Renal Denervation (ENCOReD) is set up to include thousands
of patients in randomized protocols, observational studies and
registries independent of industry. Some early results (Persu et al.,
2014a,b) from this joint effort have already been published and
suggest that it may be worthwhile searching for potential predic-
tors of response to RDN. When 2 prospective and randomized
studies that have been published (Rosa et al., 2015) and reported
(Azizi et al., 2014), plus Symplicity Flex, another sham-controlled
study very recently reported (Desch et al., 2014) are added to the 3
published studies (Esler et al., 2010; Bhatt et al., 2014; Fadl Elmula
et al., 2014) the overall picture shows that RDN is equal to drugs
in lowering BP. However, individual data suggests that there may
be cause for optimism that some truly responding patients may
be identified.
Still, before going ahead, we have to draw the lessons of
the RDN story. We must make sure that RDN is beneficial
and does no harm. Many patients have probably undergone
unneeded procedures. By a careful estimate, 20 000 renal arter-
ies have been exposed to ablation in people with hypertension
and an increasing number of cases of renal artery stenosis after
RDN are being reported (Persu et al., 2014c). It remains to
be seen whether the negative news that RDN is not for most
people will reach Time Magazine (Oz, 2012) and Der Spiegel
(Blech, 2013), or whether the old lessons (Bramley et al., 2006)
remain for clinicians who treat people with hypertension in daily
life.
THERAPEUTIC DRUG MONITORING IN RESISTANT
HYPERTENSION
In view of the major contribution of poor drug adherence to
apparent TRH, therapeutic drug monitoring (TDM) maybe a
useful tool for detecting and reducing non-adherence, leading to
substantial blood pressure (BP) improvement in this subset of
hypertensive patients. (Chung et al., 2014) have assessed cost-
effectiveness of TDM using a Markov model based on German
data and life statistics to evaluate life-years, quality-adjusted life-
years (QALYs), costs, and incremental cost-effectiveness ratios in
TRH patients receiving either TDM optimized therapy or stan-
dard best medical therapy. Efficacy of TDM was modeled by
reducing risk of hypertension-related morbidity and mortality.
The authors showed that TDM is a cost-effective health care inter-
vention in patients diagnosed with TRH, and that this finding
is valid for a wide range of patients, irrespective of age and sex
(Chung et al., 2014).
Poor drug adherence in apparent TRH is a serious issue that
has drawn the attention of experienced clinicians for many years
(Gifford, 1988; Klein, 1988). Recently, in a study of 84 patients
taking on average 5 antihypertensive drugs it was shown by mea-
surements that no drug was detectable in the blood in 34.5%
of the patients, and 65.5% of the patients fulfilled the crite-
ria of non-adherence (Ceral et al., 2011). Other investigators
have provided similar results (Jung et al., 2013; Strauch et al.,
2013; Tomaszewski et al., 2014). Beyond the clinical challenge of
convincing people with severe hypertension to take their anti-
hypertensive medication in order to control their high blood
pressure and improve their prognosis, changes in drug adherence
over time may have major, unpredictable effects on the results of
clinical trials including patients with apparent TRH. People may
change their behavior when given special attention in research
(the Hawthorne-effect). This may introduce important biases,
as patients with assumed TRH but with poor drug adherence,
may start taking their drugs when exposed to additional inter-
vention. We postulate that much of the recent controversy with
RDN can be explained in this way (Esler et al., 2010; Bhatt et al.,
2014).
Clinical assessment of non-adherence in routine practice is
challenging (Burnier et al., 2003). Drug adherence is usually
investigated using written patient’s diary or somewhat more
sophisticated by electronic pill boxes, or blood and urine mea-
surements of prescribed drugs. Measurements of drugs can pro-
vide interesting information, but are not often used in practical
clinical work especially in primary care, and the cost has been
prohibitive until recently. Neither patient’s diary nor electronic
pill boxes are perfectly reliable to ensure drug intake. The only
methods that 100% ensures true drug intake is witnessed drug
intake, an approach that may yield quite interesting results in
patients with TRH (Fadl Elmula et al., 2013, 2014). However,
while witnessed intake of drugs may identify adherent patients for
immediate inclusion into a study, this method is not particularly
practical in the long-run for the follow-up in clinical practice or
research.
In the long run, TDM in body fluids may thus prove the
best tool for evaluation and improvement of adherence to drug
therapy (Brinker et al., 2014). This approach allows an objec-
tive surveillance of patient adherence by repeatedly measuring
concentrations of antihypertensive drugs in blood and urine.
Moreover, when non-adherent patients were confronted with
their low or undetectable drug levels and were provided addi-
tional counseling to overcome barriers of adherence, blood pres-
sure control improved considerably without intensification of
therapy (Brinker et al., 2014). While several studies as pointed
out above focused on the objective exclusion or confirmation of
non-adherence, this recent study (Brinker et al., 2014) utilized
the information gained from TDMmeasurements for therapeutic
purposes. The TDM results were discussed with the non-adherent
patients to explore barriers to adherence and counseling was pro-
vided to overcome these barriers. During follow-up, SBP was
reduced by 46 ± 10mmHg in non-adherent compared to 12 ±
17mmHg in adherent patients, without intensification of the
antihypertensive therapy (Brinker et al., 2014).
TDM identifies and helps to resolve the key problem in
many—possibly the majority—of patients with apparent TRH—
that is poor adherence to prescribed drug regimen. As previously
shown, the cost-effectiveness of this approach is supported by a
solid rationale (Chung et al., 2014) and should not be compared
to similar analyses of controversial device intervention (Geisler
et al., 2012; Dorenkamp et al., 2013; Gladwell et al., 2014) in
apparent TRH patients. So far, such analyses were indeed based
on Symplicity HTN-2, an unblinded study largely open to the
Hawthorne and placebo effects, whose results could not be repli-
cated in any of five randomized trials published or presented in
2014.
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